心衰严重程度对二尖瓣经导管边缘到边缘瓣膜修复术死亡率益处的影响。

IF 3.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Clinical Research in Cardiology Pub Date : 2025-07-01 Epub Date: 2024-07-24 DOI:10.1007/s00392-024-02490-7
Valeria Magni, Marianna Adamo, Elisa Pezzola, Antonio Popolo Rubbio, Cristina Giannini, Giulia Masiero, Carmelo Grasso, Paolo Denti, Arturo Giordano, Federico De Marco, Antonio L Bartorelli, Matteo Montorfano, Cosmo Godino, Cesare Baldi, Francesco De Felice, Annalisa Mongiardo, Ida Monteforte, Emmanuel Villa, Gabriele Crimi, Maurizio Tusa, Luca Testa, Lisa Serafini, Dario Cani, Giacinta Guarini, Alda Huqi, Marco Sesana, Marco De Carlo, Francesco Maisano, Giuseppe Tarantini, Corrado Tamburino, Francesco Bedogni, Marco Metra
{"title":"心衰严重程度对二尖瓣经导管边缘到边缘瓣膜修复术死亡率益处的影响。","authors":"Valeria Magni, Marianna Adamo, Elisa Pezzola, Antonio Popolo Rubbio, Cristina Giannini, Giulia Masiero, Carmelo Grasso, Paolo Denti, Arturo Giordano, Federico De Marco, Antonio L Bartorelli, Matteo Montorfano, Cosmo Godino, Cesare Baldi, Francesco De Felice, Annalisa Mongiardo, Ida Monteforte, Emmanuel Villa, Gabriele Crimi, Maurizio Tusa, Luca Testa, Lisa Serafini, Dario Cani, Giacinta Guarini, Alda Huqi, Marco Sesana, Marco De Carlo, Francesco Maisano, Giuseppe Tarantini, Corrado Tamburino, Francesco Bedogni, Marco Metra","doi":"10.1007/s00392-024-02490-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To assess the interaction between heart failure (HF) severity and optimal reduction of secondary mitral regurgitation (SMR) on mortality in patients undergoing transcatheter edge-to-edge repair (M-TEER).</p><p><strong>Methods and results: </strong>Among 1656 patients included in the Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) 984 had SMR and complete data on advanced HF. Advanced HF was defined as NYHA class III or IV, left ventricular ejection fraction ≤ 30%, and > 1 HF hospitalization during the last 12 months. Optimal M-TEER was defined as residual SMR ≤ 1 + at discharge. One hundred sixteen patients (11.8%) had advanced HF. Achievement of an optimal SMR reduction was similar in patients with and without advanced HF (65% and 60% respectively). Advanced HF was an independent predictor of 2-year all-cause death (adjusted HR 1.52, 95% CI 1.09-2.10). Optimal M-TEER, as compared to a no-optimal M-TEER, was associated with a reduced risk of death both in patients with advanced (HR 0.55, 95% CI 0.32-0.97; p = 0.039) and no-advanced HF (HR 0.59, 95% CI 0.46-0.78; p < 0.001; p = 0.778 for interaction).</p><p><strong>Conclusions: </strong>Advanced HF is associated with poor outcome in patients undergoing M-TEER. However, an optimal SMR reduction reduces the risk of 2-year mortality regardless of HF severity.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"836-845"},"PeriodicalIF":3.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202617/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair.\",\"authors\":\"Valeria Magni, Marianna Adamo, Elisa Pezzola, Antonio Popolo Rubbio, Cristina Giannini, Giulia Masiero, Carmelo Grasso, Paolo Denti, Arturo Giordano, Federico De Marco, Antonio L Bartorelli, Matteo Montorfano, Cosmo Godino, Cesare Baldi, Francesco De Felice, Annalisa Mongiardo, Ida Monteforte, Emmanuel Villa, Gabriele Crimi, Maurizio Tusa, Luca Testa, Lisa Serafini, Dario Cani, Giacinta Guarini, Alda Huqi, Marco Sesana, Marco De Carlo, Francesco Maisano, Giuseppe Tarantini, Corrado Tamburino, Francesco Bedogni, Marco Metra\",\"doi\":\"10.1007/s00392-024-02490-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To assess the interaction between heart failure (HF) severity and optimal reduction of secondary mitral regurgitation (SMR) on mortality in patients undergoing transcatheter edge-to-edge repair (M-TEER).</p><p><strong>Methods and results: </strong>Among 1656 patients included in the Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) 984 had SMR and complete data on advanced HF. Advanced HF was defined as NYHA class III or IV, left ventricular ejection fraction ≤ 30%, and > 1 HF hospitalization during the last 12 months. Optimal M-TEER was defined as residual SMR ≤ 1 + at discharge. One hundred sixteen patients (11.8%) had advanced HF. Achievement of an optimal SMR reduction was similar in patients with and without advanced HF (65% and 60% respectively). Advanced HF was an independent predictor of 2-year all-cause death (adjusted HR 1.52, 95% CI 1.09-2.10). Optimal M-TEER, as compared to a no-optimal M-TEER, was associated with a reduced risk of death both in patients with advanced (HR 0.55, 95% CI 0.32-0.97; p = 0.039) and no-advanced HF (HR 0.59, 95% CI 0.46-0.78; p < 0.001; p = 0.778 for interaction).</p><p><strong>Conclusions: </strong>Advanced HF is associated with poor outcome in patients undergoing M-TEER. However, an optimal SMR reduction reduces the risk of 2-year mortality regardless of HF severity.</p>\",\"PeriodicalId\":10474,\"journal\":{\"name\":\"Clinical Research in Cardiology\",\"volume\":\" \",\"pages\":\"836-845\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202617/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research in Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00392-024-02490-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00392-024-02490-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:目的:评估心力衰竭(HF)严重程度与继发性二尖瓣反流(SMR)最佳缓解程度对接受经导管边缘到边缘修补术(M-TEER)患者死亡率的相互影响:在意大利介入心脏病学会(GIse)二尖瓣反流经导管治疗登记处(GIOTTO)纳入的1656名患者中,有984名患者有SMR和晚期HF的完整数据。晚期 HF 的定义是 NYHA III 级或 IV 级,左心室射血分数≤30%,在过去 12 个月中有 1 次以上 HF 住院治疗。最佳 M-TEER 的定义是出院时残余 SMR ≤ 1 +。116 名患者(11.8%)患有晚期心房颤动。晚期和非晚期心房颤动患者的最佳 SMR 降低率相似(分别为 65% 和 60%)。晚期心房颤动是两年全因死亡的独立预测因素(调整后 HR 1.52,95% CI 1.09-2.10)。与非最佳 M-TEER 相比,最佳 M-TEER 可降低晚期(HR 0.55,95% CI 0.32-0.97;P = 0.039)和非晚期 HF 患者的死亡风险(HR 0.59,95% CI 0.46-0.78;P 结论:晚期心房颤动与接受 M-TEER 的患者的不良预后有关。然而,无论心房颤动严重程度如何,最佳的 SMR 降低率都能降低 2 年死亡风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair.

Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair.

Background: To assess the interaction between heart failure (HF) severity and optimal reduction of secondary mitral regurgitation (SMR) on mortality in patients undergoing transcatheter edge-to-edge repair (M-TEER).

Methods and results: Among 1656 patients included in the Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) 984 had SMR and complete data on advanced HF. Advanced HF was defined as NYHA class III or IV, left ventricular ejection fraction ≤ 30%, and > 1 HF hospitalization during the last 12 months. Optimal M-TEER was defined as residual SMR ≤ 1 + at discharge. One hundred sixteen patients (11.8%) had advanced HF. Achievement of an optimal SMR reduction was similar in patients with and without advanced HF (65% and 60% respectively). Advanced HF was an independent predictor of 2-year all-cause death (adjusted HR 1.52, 95% CI 1.09-2.10). Optimal M-TEER, as compared to a no-optimal M-TEER, was associated with a reduced risk of death both in patients with advanced (HR 0.55, 95% CI 0.32-0.97; p = 0.039) and no-advanced HF (HR 0.59, 95% CI 0.46-0.78; p < 0.001; p = 0.778 for interaction).

Conclusions: Advanced HF is associated with poor outcome in patients undergoing M-TEER. However, an optimal SMR reduction reduces the risk of 2-year mortality regardless of HF severity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Research in Cardiology
Clinical Research in Cardiology 医学-心血管系统
CiteScore
11.40
自引率
4.00%
发文量
140
审稿时长
4-8 weeks
期刊介绍: Clinical Research in Cardiology is an international journal for clinical cardiovascular research. It provides a forum for original and review articles as well as critical perspective articles. Articles are only accepted if they meet stringent scientific standards and have undergone peer review. The journal regularly receives articles from the field of clinical cardiology, angiology, as well as heart and vascular surgery. As the official journal of the German Cardiac Society, it gives a current and competent survey on the diagnosis and therapy of heart and vascular diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信